Gene editing in T cell therapy

Yongping Zhang^{a, b, #},
Wei Mu^{a, c, #},
Haoyi Wang^{a, c
, ,}

a.
State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100190, China
b.
Department of Hematology, Aerospace Center Hospital, Aerospace Clinical Medical College, Peking University, Beijing 100049, China
c.
University of Chinese Academy of Sciences, Beijing 100049, China

More Information

Corresponding author: E-mail address: wanghaoyi@ioz.ac.cn (Haoyi Wang)

These two authors contributed equally to this work.

摘要

- /
- /
Abstract: The adoptive transfer of engineered T cells for the treatment of cancer, autoimmunity, and infectious disease is a rapidly growing field that has shown great promise. Gene editing holds tremendous potential for further improvements of T cell therapy. Here we review the applications of gene editing in various T cell therapies, focusing on antiviral strategies and cancer immunotherapies, and discuss the challenges and future prospects.
- Gene editing /
- CRISPR-Cas9 /
- T cells
These two authors contributed equally to this work.
注释:

HTML全文

参考文献(122)

[1]	Ahmed, N., Brawley, V.S., Hegde, M. et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma J. Clin. Oncol., 33 (2015),pp. 1688-1696
[2]	Aparicio, S., Hidalgo, M., Kung, A.L. Examining the utility of patient-derived xenograft mouse models Nat. Rev. Cancer, 15 (2015),pp. 311-316
[3]	Barber, D.L., Wherry, E.J., Masopust, D. et al. Restoring function in exhausted CD8 T cells during chronic viral infection Nature, 439 (2006),pp. 682-687
[4]	Beane, J.D., Lee, G., Zheng, Z. et al. Clinical scale zinc finger nuclease-mediated gene editing of PD-1 in tumor infiltrating lymphocytes for the treatment of metastatic melanoma Mol. Ther., 23 (2015),pp. 1380-1390
[5]	Berdien, B., Mock, U., Atanackovic, D. et al. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer Gene Ther., 21 (2014),pp. 539-548
[6]	Bogdanove, A.J., Voytas, D.F. TAL effectors: customizable proteins for DNA targeting Science, 333 (2011),pp. 1843-1846
[7]	Brentjens, R.J., Davila, M.L., Riviere, I. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Sci. Transl. Med., 5 (2013)
[8]	Brown, C.E., Badie, B., Barish, M.E. et al. Clin. Cancer Res., 21 (2015),pp. 4062-4072
[9]	Cannon, P.M., Kohn, D.B., Kiem, H.P. HIV eradication–from Berlin to Boston Nat. Biotechnol., 32 (2014),pp. 315-316
[10]	Cho, S.W., Kim, S., Kim, J.M. et al. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease Nat. Biotechnol., 31 (2013),pp. 230-232
[11]	Cole, D.J., Weil, D.P., Shilyansky, J. et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen Cancer Res., 55 (1995),pp. 748-752
[12]	Couzin-Frankel, J. Breakthrough of the year 2013. Cancer immunotherapy Science, 342 (2013),pp. 1432-1433
[13]	Deng, H., Liu, R., Ellmeier, W. et al. Identification of a major co-receptor for primary isolates of HIV-1 Nature, 381 (1996),pp. 661-666
[14]	Didigu, C.A., Wilen, C.B., Wang, J. et al. Blood, 123 (2014),pp. 61-69
[15]	Doitsh, G., Galloway, N.L., Geng, X. et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection Nature, 505 (2014),pp. 509-514
[16]	Doudna, J.A., Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9 Science, 346 (2014),p. 1258096
[17]	Douek, D.C., Brenchley, J.M., Betts, M.R. et al. Nature, 417 (2002),pp. 95-98
[18]	Dragic, T., Litwin, V., Allaway, G.P. et al. Nature, 381 (1996),pp. 667-673
[19]	Dudley, M.E., Wunderlich, J.R., Robbins, P.F. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science, 298 (2002),pp. 850-854
[20]	Dudley, M.E., Yang, J.C., Sherry, R. et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens J. Clin. Oncol., 26 (2008),pp. 5233-5239
[21]	Ebina, H., Kanemura, Y., Misawa, N. et al. A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector PLoS One, 10 (2015),p. e0120047
[22]	Ebina, H., Misawa, N., Kanemura, Y. et al. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus Sci. Rep., 3 (2013),p. 2510
[23]	Eyquem, J., Mansilla-Soto, J., Giavridis, T. et al. Nature, 543 (2017),pp. 113-117
[24]	Finney, H.M., Akbar, A., Lawson, A. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR chain J. Immunol., 172 (2004),pp. 104-113
[25]	Freeman, G.J., Long, A.J., Iwai, Y. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J. Exp. Med., 192 (2000),pp. 1027-1034
[26]	Frock, R.L., Hu, J., Meyers, R.M. et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases Nat. Biotechnol., 33 (2015),pp. 179-186
[27]	Gabriel, R., Lombardo, A., Arens, A. et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity Nat. Biotechnol., 29 (2011),pp. 816-823
[28]	Gorak-Stolinska, P., Truman, J.P., Kemeny, D.M. et al. Activation-induced cell death of human T-cell subsets is mediated by Fas and granzyme B but is independent of TNF-alpha J. Leukoc. Biol., 70 (2001),pp. 756-766
[29]	Gross, G., Waks, T., Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc. Natl. Acad. Sci. U. S. A., 86 (1989),pp. 10024-10028
[30]	Grupp, S.A., Kalos, M., Barrett, D. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N. Engl. J. Med., 368 (2013),pp. 1509-1518
[31]	Hamid, O., Robert, C., Daud, A. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N. Engl. J. Med., 369 (2013),pp. 134-144
[32]	Hendel, A., Bak, R.O., Clark, J.T. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells Nat. Biotechnol., 33 (2015),p. 985
[33]	Hirano, F., Kaneko, K., Tamura, H. et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res., 65 (2005),pp. 1089-1096
[34]	Hodi, F.S., O'Day, S.J., McDermott, D.F. et al. Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med., 363 (2010),pp. 711-723
[35]	Hoffman, R.M. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts Nat. Rev. Cancer, 15 (2015),pp. 451-452
[36]	Hoffmann, C. The epidemiology of HIV coreceptor tropism Eur. J. Med. Res., 12 (2007),pp. 385-390
[37]	Holt, N., Wang, J., Kim, K. et al. Nat. Biotechnol., 28 (2010),pp. 839-847
[38]	Hsu, P.D., Lander, E.S., Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering Cell, 157 (2014),pp. 1262-1278
[39]	Hu, W., Kaminski, R., Yang, F. et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection Proc. Natl. Acad. Sci. U. S. A., 111 (2014),pp. 11461-11466
[40]	Hultquist, J.F., Schumann, K., Woo, J.M. et al. A Cas9 ribonucleoprotein platform for functional genetic studies of HIV-host interactions in primary human T cells Cell Rep., 17 (2016),pp. 1438-1452
[41]	Hutter, G., Nowak, D., Mossner, M. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation N. Engl. J. Med., 360 (2009),pp. 692-698
[42]	Imai, C., Mihara, K., Andreansky, M. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia Leukemia, 18 (2004),pp. 676-684
[43]	June, C.H., Riddell, S.R., Schumacher, T.N. Adoptive cellular therapy: a race to the finish line Sci. Transl. Med., 7 (2015)
[44]	Kalams, S.A., Buchbinder, S.P., Rosenberg, E.S. et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection J. Virol., 73 (1999),pp. 6715-6720
[45]	Kalos, M., Levine, B.L., Porter, D.L. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci. Transl. Med., 3 (2011),p. 9
[46]	Karwacz, K., Bricogne, C., MacDonald, D. et al. EMBO Mol. Med., 3 (2011),pp. 581-592
[47]	Katz, S.C., Burga, R.A., McCormack, E. et al. Clin. Cancer Res., 21 (2015),pp. 3149-3159
[48]	Kershaw, M.H., Westwood, J.A., Parker, L.L. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Clin. Cancer Res., 12 (2006),pp. 6106-6115
[49]	Khalil, D.N., Smith, E.L., Brentjens, R.J. et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy Nat. Rev. Clin. Oncol., 13 (2016),pp. 273-290
[50]	Kim, D., Bae, S., Park, J. et al. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells Nat. Methods, 12 (2015),pp. 237-243
[51]	Kleinstiver, B.P., Pattanayak, V., Prew, M.S. et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects Nature, 529 (2016),pp. 490-495
[52]	Kowolik, C.M., Topp, M., Gonzalez, S. et al. Cancer Res., 66 (2006),pp. 10995-11004
[53]	Kunkele, A., Johnson, A.J., Rolczynski, L.S. et al. Cancer Immunol. Res., 3 (2015),pp. 368-379
[54]	Lamers, C.H., Sleijfer, S., van Steenbergen, S. et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity Mol. Ther., 21 (2013),pp. 904-912
[55]	Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Lancet, 385 (2015),pp. 517-528
[56]	Lee, H., Park, S., Choi, B.K. et al. J. Immunol., 169 (2002),pp. 4882-4888
[57]	Li, C., Guan, X.W., Du, T. et al. J. Gen. Virol., 96 (2015),pp. 2381-2393
[58]	Li, L., Krymskaya, L., Wang, J. et al. Mol. Ther., 21 (2013),pp. 1259-1269
[59]	Liu, R., Paxton, W.A., Choe, S. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection Cell, 86 (1996),pp. 367-377
[60]	Liu, X., Zhang, Y., Cheng, C. et al. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells Cell Res., 27 (2017),pp. 154-157
[61]	Lloyd, A., Vickery, O.N., Laugel, B. Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies Front. Immunol., 4 (2013),p. 221
[62]	Lombardo, A., Cesana, D., Genovese, P. et al. Site-specific integration and tailoring of cassette design for sustainable gene transfer Nat. Methods, 8 (2011),pp. 861-869
[63]	Louis, C.U., Savoldo, B., Dotti, G. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma Blood, 118 (2011),pp. 6050-6056
[64]	MacLeod, D.T., Antony, J., Martin, A.J. et al. Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells Mol. Ther., 25 (2017),pp. 949-961
[65]	Maher, S., Toomey, D., Condron, C. et al. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack Immunol. Cell Biol., 80 (2002),pp. 131-137
[66]	Mandal, P.K., Ferreira, L.M.R., Collins, R.L. et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9 Cell Stem Cell, 15 (2014),pp. 643-652
[67]	Maude, S.L., Frey, N., Shaw, P.A. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia N. Engl. J. Med., 371 (2014),pp. 1507-1517
[68]	McCune, J.M. Nature, 410 (2001),pp. 974-979
[69]	Mei, Y., Wang, Y., Chen, H. et al. Recent progress in CRISPR/Cas9 technology J. Genet. Genomics, 43 (2016),pp. 63-75
[70]	Menger, L., Sledzinska, A., Bergerhoff, K. et al. TALEN-mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral T-cell persistence and rejection of established tumors Canc. Res., 76 (2016),pp. 2087-2093
[71]	Miller, J.C., Holmes, M.C., Wang, J. et al. An improved zinc-finger nuclease architecture for highly specific genome editing Nat. Biotechnol., 25 (2007),pp. 778-785
[72]	Milone, M.C., Fish, J.D., Carpenito, C. et al. Mol. Ther., 17 (2009),pp. 1453-1464
[73]	Morgan, R.A., Dudley, M.E., Wunderlich, J.R. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes Science, 314 (2006),pp. 126-129
[74]	Morgan, R.A., Yang, J.C., Kitano, M. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol. Ther., 18 (2010),pp. 843-851
[75]	Mussolino, C., Alzubi, J., Fine, E.J. et al. TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity Nucleic Acids Res., 42 (2014),pp. 6762-6773
[76]	Nguyen, L.T., Ohashi, P.S. Clinical blockade of PD1 and LAG3–potential mechanisms of action Nat. Rev. Immunol., 15 (2015),pp. 45-56
[77]	Nishimura, H., Nose, M., Hiai, H. et al. Immunity, 11 (1999),pp. 141-151
[78]	Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy Nat. Rev. Cancer, 12 (2012),pp. 252-264
[79]	Park, J.R., Digiusto, D.L., Slovak, M. et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma Mol. Ther., 15 (2007),pp. 825-833
[80]	Patel, S., Jones, R.B., Nixon, D.F. et al. T-cell therapies for HIV: preclinical successes and current clinical strategies Cytotherapy, 18 (2016),pp. 931-942
[81]	Peled, A., Petit, I., Kollet, O. et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4 Science, 283 (1999),pp. 845-848
[82]	Perez, E.E., Wang, J., Miller, J.C. et al. Nat. Biotechnol., 26 (2008),pp. 808-816
[83]	Pignatti, P., Massa, M., Travaglino, P. et al. Activation-induced cell death and Fas-induced apoptosis in patients with systemic or polyarticular juvenile idiopathic arthritis Clin. Exp. Rheumatol., 19 (2001),pp. 339-344
[84]	Poirot, L., Philip, B., Schiffer-Mannioui, C. et al. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies Cancer Res., 75 (2015),pp. 3853-3864
[85]	Qasim, W., Zhan, H., Samarasinghe, S. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells Sci. Transl. Med., 9 (2017)
[86]	Qu, X., Wang, P., Ding, D. et al. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells Nucleic Acids Res., 41 (2013),pp. 7771-7782
[87]	Ren, J., Liu, X., Fang, C. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition Clin. Cancer Res., 23 (2017),pp. 2255-2266
[88]	Ren, J., Zhang, X., Liu, X. et al. A versatile system for rapid multiplex genome-edited CAR T cell generation Oncotarget, 8 (2017),pp. 17002-17011
[89]	Ribas, A., Hamid, O., Daud, A. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma , 315 (2016),pp. 1600-1609
[90]	Rosenberg, S.A., Packard, B.S., Aebersold, P.M. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report N. Engl. J. Med., 319 (1988),pp. 1676-1680
[91]	Rosenberg, S.A., Yang, J.C., Sherry, R.M. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Clin. Cancer Res., 17 (2011),pp. 4550-4557
[92]	Samson, M., Libert, F., Doranz, B.J. et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene Nature, 382 (1996),pp. 722-725
[93]	Sather, B.D., Romano Ibarra, G.S., Sommer, K. et al. Sci. Transl. Med., 7 (2015)
[94]	Savoldo, B., Ramos, C.A., Liu, E. et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients J. Clin. Invest., 121 (2011),pp. 1822-1826
[95]	Schietinger, A., Greenberg, P.D. Tolerance and exhaustion: defining mechanisms of T cell dysfunction Trends Immunol., 35 (2014),pp. 51-60
[96]	Schumann, K., Lin, S., Boyer, E. et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins Proc. Natl. Acad. Sci. U. S. A., 112 (2015),pp. 10437-10442
[97]	Shmakov, S., Abudayyeh, O.O., Makarova, K.S. et al. Discovery and functional characterization of diverse class 2 CRISPR-cas systems Mol. Cell, 60 (2015),pp. 385-397
[98]	Slaymaker, I.M., Gao, L., Zetsche, B. et al. Rationally engineered Cas9 nucleases with improved specificity Science, 351 (2016),pp. 84-88
[99]	Su, S., Hu, B., Shao, J. et al. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients Sci. Rep., 6 (2016),p. 20070
[100]	Su, S., Hu, B., Shao, J. et al. Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients Sci. Rep., 7 (2017),p. 40272
[101]	Swarts, D.C., Jore, M.M., Westra, E.R. et al. DNA-guided DNA interference by a prokaryotic Argonaute Nature, 507 (2014),pp. 258-261
[102]	Szczepek, M., Brondani, V., Buchel, J. et al. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases Nat. Biotechnol., 25 (2007),pp. 786-793
[103]	Tebas, P., Stein, D., Tang, W.W. et al. N. Engl. J. Med., 370 (2014),pp. 901-910
[104]	Topalian, S.L., Drake, C.G., Pardoll, D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Curr. Opin. Immunol., 24 (2012),pp. 207-212
[105]	Torikai, H., Reik, A., Liu, P.Q. et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR Blood, 119 (2012),pp. 5697-5705
[106]	Torikai, H., Reik, A., Soldner, F. et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors Blood, 122 (2013),pp. 1341-1349
[107]	Tsai, S.Q., Zheng, Z., Nguyen, N.T. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases Nat. Biotechnol., 33 (2015),pp. 187-197
[108]	Urnov, F.D., Rebar, E.J., Holmes, M.C. et al. Genome editing with engineered zinc finger nucleases Nat. Rev. Genet., 11 (2010),pp. 636-646
[109]	Valton, J., Guyot, V., Marechal, A. et al. A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy Mol. Ther., 23 (2015),pp. 1507-1518
[110]	von Kalle, C., Deichmann, A., Schmidt, M. Vector integration and tumorigenesis Hum. Gene. Ther., 25 (2014),pp. 475-481
[111]	Wang, X., Wang, Y., Wu, X. et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors Nat. Biotechnol., 33 (2015),pp. 175-178
[112]	Wherry, E.J. T cell exhaustion Nat. Immunol., 12 (2011),pp. 492-499
[113]	Wherry, E.J., Kurachi, M. Molecular and cellular insights into T cell exhaustion Nat. Rev. Immunol., 15 (2015),pp. 486-499
[114]	Wilen, C.B., Wang, J., Tilton, J.C. et al. PLoS Pathog., 7 (2011),p. e1002020
[115]	Woo, S.R., Turnis, M.E., Goldberg, M.V. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape Cancer Res., 72 (2012),pp. 917-927
[116]	Xu, L., Yang, H., Gao, Y. et al. Mol. Ther., 25 (2017),pp. 1782-1789
[117]	Yang, L., Guell, M., Byrne, S. et al. Optimization of scarless human stem cell genome editing Nucleic Acids Res., 41 (2013),pp. 9049-9061
[118]	Yuan, J., Wang, J., Crain, K. et al. Mol. Ther., 20 (2012),pp. 849-859
[119]	Zetsche, B., Gootenberg, J.S., Abudayyeh, O.O. et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system Cell, 163 (2015),pp. 759-771
[120]	Zhang, Y., Zhang, X., Cheng, C. et al. Front. Med. (2017)
[121]	Zhu, W., Lei, R., Le Duff, Y. et al. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA Retrovirology, 12 (2015),p. 22
[122]	Zitvogel, L., Kroemer, G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy Oncoimmunology, 1 (2012),pp. 1223-1225